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Taurine, a sulfonie acid, has been claimed
by Roe (1—5) to be of etiological significance
In psoriasis. She has also reported good results
in the treatment of psoriasis with a low tau-
rine diet (3, 5). The theoretical basis for this
concept is considered in the discussion in this
report. To test the validity of this hypothesis,
we have given supplemental taurine to 13 pa-
tients with psoriasis.
EXPERIMENTAL PROCEDURE
Thirteen patients with psoriasis were given
daily supplomental taurine for periods ranging
from 11 days to 4 weeks (Table I). Eleven received
660 mg, administered as 330 mg bid. Case #1 re-
ceived 1.3 gm (660 mg bid) for 11 days, and Case
#3 received 990 mg (330 mg tid) for 4 weeks. All
were given the taurinc as taurine powder in gelatin
capsules, with the exception of Case #1 who was
given the taurine powder freshly dissolved in a
glass of water.
Cases #1 and #2 were hospitalized. The re-
mainder were treated as out-patients in the derma-
tology clinic. Color photographs, using Koda-
chrome II 35 mm film, were taken at weekly or
hi-weekly intervals. Judgements as to the clinical
course were based on careful examination of these
photographs, general examination of the patients,
and their subjective symptoms.
CASE HISTORIES
Case #1 is a 67-year-old white male with a
history of severe recurrent psoriasis for about
20 years. He was admitted to the Veterans
Administration Hospital on 4/11/66 with
widespread involvement of the trunk and ex-
tremities consisting of thick, scaly plaques.
After 2 weeks he was placed on a low protein
diet and Eucerin® cream (equal parts of
Aquaphor® and water). He gradually improved
to about 75% in 4 to 6 weeks. At this time,
while on the low protein diet (22 gm protein,
2500 total calories) he was given 660 mg tau-
rine freshly dissolved in water, twice daily,
for 11 days. During this period the psoriasis
continued to improve with decreased sealing and
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continued paling and thinning of the plaques.
No itching occurred. During the period of tan-
rine intake a complete blood count, urinalysis,
and blood urea nitrogen were within normal
limits.
Case 2 is a 52-year-old white male with a
history of recurrent severe psoriasis and ar-
thritis for over 20 years. He was hospitalized
at tile Veterans Administration Hospital with
extensive psoriasis involving particularly the
back, lower extremities and forearms. He
gradually improved to approximately 70% in
about one month while on a low protein diet
(22 gm. protein, total calories 2400) and using
Eucerin® cream. At this time he was given
supplemental taurine, 330 mg bid in gelatin
capsules, for 2 weeks, while continuing on the
low protein diet. During this period, the
psoriasis continued to involute and there was
no itching or other subjective symptoms. Sev-
eral blood counts and urinalyses during the
period of taurine intake were within normal
limits.
The other 11 patients in this study were
followed as out-patients in the dermatology
clinic (Table I). Cases 1—7 were on a low pro-
tein diet in which the sources of protein were
skimmed milk, cottage cheese, bread, fruit
and vegetables. All received approximately 22-.
24 gms of protein daily with the exception of
Case 4 who received 40 gms. Cases 1—5 were
on a total caloric intake designed to maintain
their present weight (iso-caloric), with a
range of 2300—2700 calories. Cases 6 and 7 were
on a low caloric intake of approximately 1000
calories. Topical therapy for Cases 1—7 was
restricted to Eucerin® cream applied once or
twice daily.
Cases #8—13 were all on a regular, uncon-
trolled diet and were given 330 mg taurine
bid daily for 4 weeks. Their psoriasis had
been rather stable for the preceding 1 to 2
months and they were on various topical
preparations (Table I) which was keeping the
psoriasis under fair control, but certainly was
not clearing the process. Three were on 10%
liquor carbonis detergens cream, one on a tar
distillate paste (Dispertar®) one on Cord-
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TABLE I
ran® cream 0.025%, and one on Kenalog®
cream 0.1%. Only one of these, Case *'10,
showed some deterioration during the 4 week
period. She had medium-sized plaques involv-
ing the elbows and knees. There was no
marked change in her condition and no
pruritus, hut examination of her photographs
revealed a gradual increase in the size of the
plaques on her right elbow. However, the right
knee was unchanged. Cases 8, 9, 11, 12, and 13
showed no change in their psoriasis during
the period of taurine ingestion and none
complained of itching during that time.
DISCUSSION
Taurine, beta-aminoethylsulfonic acid, is
conjugated with eholie acid to form tauro-
eholie acid, one of the bile acids. Methionine,
hemocystine, and cystine are convertible to
taurine through cysteine. Apparently the body
is unable to oxidize off the sulfonie acid
group of taurine as sulfate (6). The rat, dog,
and man are not capable of metabolizing
taurine (7). Taurine is almost entirely dim-
mated within 24 hours after oral or parenteral
administration. After such administration,
approximately 60 to 80% of taurine sulfur can
be recovered in the urine (8). There is no sig-
nificant increase in the urinary excretion of
sulfates after oral ingestion of taurine in man
(8, 9). The fate of taurine in dogs is the same
as that in man (10). Whereas eysteine can
substitute for cystine in a eystine deficient
diet in the rat, taurine cannot do so (11).
Taurine does not furnish sulfur for mercap-
tune acid synthesis in rats (12).
Taurine is apparently non-toxic within a
wide range. Schmidt gave single oral and
parenteral 10 gm doses of taurine to man
without harmful effect (8). Rats fed stock
diets containing 1 to 10% added taurine de-
veloped no internal pathology and grew as well
as their controls (13).
Roe (2) treated 12 chronic psoriatics with
the bile acid sequestrant, cholestyramine,
and obtained complete or partial remission in
all. Recurrence of the lesions followed cessa-
tion of therapy. Increased fecal excretion
Severity
Daily
dose
grams
Duraton Rx Local Ex Diet
11 days Euccrin®
Sex Age Locatioo
1. M 67 trunk, ex-
tremities
2. M 52 widespread
3. F 63 trunk, ex-
tremities
4. M 43 trunk, ex-
tremities
5. M 33 trunk, ex-
tremities
6. M 65 trunk, ex-
tremities
7. M 55 trunk
8. F 35 trunk, face
9. M 35 elbows,
knees
10. F 42 elbows,
knees
11. F 31 extremities
12. M 65 extremities
13. M 48 buttox,
knees
moderate
moderate
moderate
moderate
mild
mild
mild
moderate
mild
moderate
moderate
moderate
moderate
1.3
0.66
0.99
0.66
0.66
0.66
0.66
0.66
0.66
0.66
0.66
0.66
0.66
2 weeks
4 weeks
2 weeks
2 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
low prot.
iso-calor.
low prot.
iso-calor.
low prot.
iso-calor.
low prot.
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low prot.
iso-calor.
low prot.
low-calor.
low prot.
low-calor.
regular
regular
regular
regular
regular
regular
Result
yes improved
yes improved
no worse
no unchanged
no unchanged
no improved
no unchanged
no unchanged
no unchanged
no slightly
worse
no unchanged
no unchanged
no unchanged
Eucerin®
Eucerin®
Eucerin®
Eucerin®
baby oil
Eucenin®
LCD cr.
LCD cr.
LCD cr.
Dispertar®
Cordran®
0.025%
Kenalog®
0.1%
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of taurine was demonstrated during the cho-
lestyramine therapy. Subsequently, Roe (4)
reported that single 2 gm oral doses of taurine
caused pruritus and exacerbation of the lesions
in psoriasis. The itching response could be
elicited even in those in complete remission,
but not in normal control subjects. Verma
(14) gave 2 consecutive daily 2 gm doses of
taurine to patients with eczema and psoriasis
and found that itching and objective worsen-
ing occurred in both groups. It would thus
appear that the aggravating effect of such
large daily doses is non-specific for some
dermatoses.
In a later report, Roe (1) gave 200 mg of
taurine as a dietary supplement to 3 patients
with psoriasis and one control who were other-
wise on a diet containing 50 mg taurinc. This
supplement resulted in an exacerbation of the
psoriasis and also an aggravation of accom-
panying arthritis. Amelioration occurred if
the taurine intake was kept below 70 mg per
day. Metabolic balance studies revealed a re-
tention of taurine in psoriatics on a high in-
take of this material, but not in the controls.
It was felt that psoriatics may handle exoge-
nous taurinc abnormally. Roe states that tau-
rine retention is cumulative and that taurine
intake within the range of the normal diet
can cause toxic effects relative to the psoriatic
process. Roe found that in psoriatics, taurinc
supplementation caused changes in the nrinary
partition of sulfur, with reduction in the
excretion of inorganic sulfate (3). The hy-
pothesis is advanced (1, 3) and the statement
is made (5) that taurine exerts a sparing ef-
fect on the catabolism of other sulfur-contain-
ing amino-acids such as methionine and
cystine. Hence these might be available to a
greater degree than otherwise for epidcrmal
protein synthesis. However, confirmatory evi-
dence in support of this theory is not pre-
sented.
As a consequence of these findings Roe has
recommended a low taurine diet for psoriasis
and reported significant clinical improvement
in patients adhering to this program (3).
CONCLU5TON5
The results of this study fail to support the
thesis that taurine is of ctiological importance
in psoriasis. Based on Roe's data on the tan-
rine composition of foods (1, 3), Miss Alice
Hine, Clinic Dietitian at the Stanford Medi-
cal Center, has calculated the daily taurine
content of a normal diet as 50 to 150 mg.
Hence, the eleven patients receiving 660 mg
daily received at least 4 to 10 times the aver-
age daily taurinc intake, while those receiv-
ing 990 mg and 1.3 gm were even higher. De-
spite this, only 2, of whom one was on 990 mg
for 4 weeks, became worse. This is hardly less
than would he expected in view of the periodic
remissions and exacerbations to be expected in
psoriasis, particularly in outpatients in a 2 to
4 week period.
Of particular interest is Case y1 who was
hospitalized and received 1.3 gm taurinc
daily for 11 days, and Case 2 who was hos-
pitalized and received 660 mg for 2 weeks,
while they were on a diet containing only 22
gm of protein. Both used only Eucerin®
cream. They continued to improve despite
the excessive taurine intake. Roe states (1)
that the aggravating effect of added taurine is
most apt to be revealed when the patient is
on a low taurine intake. Seven of our patients
(Cases 1—7) were on a low protein diet and
Eucerin® cream or "baby oil". Six of these
were on a 22 gm protein intake, and one on a
40 gm intake. The principal source of protein
was skimmed milk, cottage cheese, and bread.
The calculated taurinc content of these diets
was very low, undoubtedly below 25 mg. De-
spite this, only one patient, who received 990
mg taurine daily, became worse in a 4 week
period and she suffered no acute, exacerbating
symptoms.
It is apparent from reading this report that
a number of our patients had improved while
on a low protein diet prior to taking sup-
plementary taurine. Since taurine is present
mainly in animal protein and sea food, a low
protein diet by definition is a low taurine
diet. We are currently engaged in a study of
the effect of a low protein diet on psoriasis,
but are not prepared to make a statement in
this regard at the present time. If taurine is
an etiological or aggravating factor in psoria-
sis, this should be evident if the patient is on
a low protein-low taurine intake at the time
of taurine supplementation.
The theoretical grounds for postulating a
mechanism whereby taurinc might be expected
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to be a causative or aggravating factor in
psoriasis are extremely tenuous in our opin-
ion. It is hard to conceive of exogenous taurine
which has been demonstrated for all practical
purposes as being of no metabolic signifi-
cance for man, dog, and the rat as being of
any importance in the psoriatie process.
Verma (14) states that psoriasis is common
in the state of Gujarat, India, where the ma-
jority of the population is vegetarian and
even their non-animal protein intake is very
limited. He therefore doubts that taurine in-
gestion is a major etiological factor in psoria-
sis.
5UMMARY
Thirteen patients with psoriasis were given
supplemental taurine ranging from 660 mg to
1.3 gm daily in divided doses for 11 days to 4
weeks. Seven of these were otherwise on a low
protein diet and six were on a regular diet.
Three of the patients improved, 2 became
worse, and S were unchanged. The etiological
role of taurine in psoriasis is disputed.
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